TruScreen Limited has provided a copy of its June 2018 Shareholder Newsletter. This provides an update on TruScreen’s performance and highlights key initiatives underway.
In particular, the company is now seeing its efforts translating into commercial progress and recent sales indicate that it has reached a major turning point.
The FY18 preliminary results will be released shortly and whilst commercial sales were a modest increase on FY17, sales since year-end have shown month on month growth. This is mainly as a result of gaining CFDA approval for the TruScreen2 device in China, as well as growing recognition and validation for the benefits the TruScreen technology brings.
The Shareholder Newsletter will also be available for viewing on the company website http://truscreen.com/investor-centre/reports-presentations/.
For more information visit www.truscreen.com or contact:
TruScreen Chief Executive Officer
Phone: +64 27 246 2505
TruScreen’s real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection.